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Background: Heart failure (HF) is the most common reason for hospitalization among Medicare beneficiaries. This study evaluates 
hospitalization, subsequent treatment modifications post hospitalization and treatment adherence (for ACEI, ARB, BB and AA) among HF 
patients recently diagnosed in a real world setting in the US.
methods: Using administrative claims data from the Truven MarketScan database, this retrospective cohort study included adult patients 
with ≥2 HF-related medical claims between April 2009 and March 2012 and with a minimum of 12 months pre-and post-index continuous 
medical and pharmacy eligibility. Index date was defined as the first HF-related medical claim between April 2009 and March 2012. Patients 
with a HF diagnosis in the 12 months pre-index period were excluded. All-cause and HF-related hospitalization, length of stay (LOS), 
change in treatment pattern post HF hospitalization (15-day period), treatment adherence [medication possession ratio (MPR), proportion 
of days covered (PDC)] and persistence rate over 12 months was determined.
results: 235,758 recently diagnosed patients with a median follow-up of 28 months were included in the analysis. A total of 74% patients 
had at least one all-cause hospitalization, with a mean of 1.11 (SD: 0.98) per year and LOS of 7.19 (8.69) days. Corresponding values 
for HF hospitalization were 21.9%, 0.18 (0.36) per year and 5.85 (5.45) days, respectively. Post first HF hospitalization, more patients on 
dual and triple therapy remained on the same treatment (73-88%) compared to those patients treated with monotherapy (60-73%). Among 
patients on ACEI and BB monotherapy, 21% and 17% transitioned to ACEI+BB combination. Of patients on ACEI+BB, 9% transitioned to 
ACEI+BB+AA. Of the untreated patients, 17% received treatment post HF hospitalization. The median MPR and PDC were >0.93 (range: 
0.03-1.00) and >0.65 (>0 - 1), respectively. Considering a gap period of 30 days, persistence ranged between 41% (AA) to 52% (BB).
conclusion:  Study results suggest that the treatment for HF patients does not change substantially post HF hospitalization. Overall, HF 
patients showed good adherence and moderate persistence to the treatment.
